A Phase IB, Multicenter, Randomized, Placebo-Controlled, Double-blind, Parallel-Arm, Multiple-Dose Study to assess the safety, tolerability, and Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease
A study assessing the safety and effectiveness of study drug Crenezumab in patients with mild to moderate Alzheimer's Disease
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAO8808
U.S. Govt. ID: NCT02353598
Contact: Evelyn Dominguez: 212-305-2371 / edd5@columbia.edu
Additional Study Information: The purpose of this study is to better understand why certain patients are more likely to respond totreatment than others, to facilitate the development of personalized medicinesto get the rightmedicine to the right patient. To achieve this goal, samples of blood will be collected from patients with Alzheimer's for future research. The sample will be used by Genentech researchers and other researchers partnering with Genentech for future research related to Alzheimers disease and related diseases and/or the use of a study drug called crenezumab in disease therapy and diagnosis, and its side effects.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Do weigh between 99 and 265 pounds? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Evelyn Dominguez